TICKERNERD
Menu
CRBPCRBPHealthcare · Biotechnology

CRBP Stock Forecast: Corbus Pharmaceuticals Holdings, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$5.27
−4.01% on the day

The 9 Wall Street analysts covering Corbus Pharmaceuticals Holdings, Inc. hold a median 12-month price target of $34 — +545.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$111.8M
Ticker Nerd rank
19 / 100
Median analyst target
$34
Analysts covering
9
Revenue$0.0
Operating income−$36.2M
Net income−$35.0M
Free cash flow−$29.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−16.9%
1M
−50.3%
YTD
−35.3%
1Y
−60.7%
From 52W high
−72.8%
From 52W low
0.0%
$5
$19
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRBP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Corbus Pharmaceuticals Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
19 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
76
Size
75
Quality
48
Volatility
33
Revisions
30
Momentum
27
Growth
17
Issuance
14
Value
12

Accruals (76): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (12): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CRBP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRBP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Jan 26Apr 26Jul 26Oct 26CRBPHigh $48Median $34Low $17

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $17Median $34High $48

The green dot is the last close — the median target sits +545.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
14 Sept 2026HC Wainwright & Co.ReiteratesBuy$35
7 Aug 2026HC Wainwright & Co.MaintainsBuy—
7 Aug 2026HC Wainwright & Co.MaintainsBuy$40 → $35
7 Aug 2026OppenheimerMaintainsOutperform—
7 Aug 2026OppenheimerMaintainsOutperform$52 → $48
23 June 2026MizuhoMaintainsOutperform$44 → $34
23 June 2026MizuhoMaintainsOutperform—
17 June 2026OppenheimerMaintainsOutperform$54 → $52
17 June 2026OppenheimerMaintainsOutperform—
27 May 2026WedbushMaintainsOutperform—
26 May 2026HC Wainwright & Co.ReiteratesBuy—
22 May 2026MizuhoMaintainsOutperform—
13 May 2026GuggenheimReiteratesBuy—
13 May 2026JefferiesMaintainsBuy—
13 May 2026OppenheimerMaintainsOutperform—
29 Apr 2026GuggenheimInitiatesBuy—
10 Mar 2026OppenheimerMaintainsOutperform—
13 Nov 2025RBC CapitalMaintainsOutperform—
20 Oct 2025HC Wainwright & Co.ReiteratesBuy—
20 Oct 2025WedbushMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRBP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CRBP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Corbus Pharmaceuticals Holdings, Inc. returned −60.7% against +16.2% for the S&P 500, dividends included.

CRBP vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Jan 26Apr 26Jul 26Oct 26CRBPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CRBP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
9
Fundamentals

Corbus Pharmaceuticals Holdings, Inc. (CRBP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.0×

Cheaper than 83% of US stocks

Price / sales
—
Price / book
1.1×

Cheaper than 70% of US stocks

EV / EBITDA
0.0×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−95.6%

Higher than 14% of US stocks

Return on assets
−53.0%

Higher than 7% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Corbus Pharmaceuticals Holdings, Inc. (CRBP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Corbus Pharmaceuticals Holdings, Inc. has a market value of $111.8M and an enterprise value of −$1.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$101.9M.

  • Diluted earnings per share, trailing twelve months: $−6.19.

  • Free cash flow in the twelve months to 30 June 2026: −$86.7M.

  • Shares outstanding: 17.7M.

  • Trailing P/E: −1.0×; forward P/E: −1.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Corbus Pharmaceuticals Holdings, Inc. employs 36 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

CRBP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRBPCorbus Pharmaceuticals Holdings, Inc.$111.8M
19
ANIXAnixa Biosciences, Inc.$97.6M
72
CNXUConexeu Sciences, Inc.$97.3M
1
BMEABiomea Fusion, Inc.$96.9M
55
PYPDPolyPid Ltd.$99.5M
56
PLYXPolaryx Therapeutics, Inc.$99.7M
16
AARDAardvark Therapeutics, Inc.$102.6M
19

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Corbus Pharmaceuticals Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRBP news & analysis

Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer

GlobeNewsWire · 29 Sept 2026positive

Corbus Pharmaceuticals announced that the first patient has been dosed in its TEMPO-1 registrational study of CRB-701, a next-generation Nectin-4 targeted antibody drug conjugate, in second-line and beyond oropharyngeal squamous cell carcinoma. The company noted that OPSCC incidence and prevalence are rising in the U.S., largely driven by HPV infection, with an estimated 14,000 patients eligible for treatment annually.

Why it matters — This milestone advances CRB-701 into a registrational study targeting a growing patient population in oropharyngeal cancer, a key clinical development step for CRBP's pipeline.

Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?

Zacks Investment Research · 17 Sept 2026positive

Zacks reports that Corbus Pharmaceuticals announced positive obesity study data, which boosts the company's cannabinoid-based strategy. The report also highlights CRB-701 and the company's cash needs as additional factors for investors to consider.

Why it matters — CRBP watchers would care because the positive obesity data supports the company's core cannabinoid strategy, while the status of CRB-701 and its cash position add important context to its outlook.

Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study

MarketBeat · 15 Sept 2026neutral

Corbus Pharmaceuticals reported top-line results from CANYON-1, a Phase 1b placebo-controlled trial of CRB-913, an oral CB1 inverse agonist for obesity. The 12-week study enrolled 254 patients with an average BMI of approximately 37 across 15 U.S. sites.

Why it matters — The findings provide an early readout on the safety and efficacy of CRB-913, a key candidate in Corbus' obesity pipeline.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss Therapy Transcript

Seeking Alpha · 14 Sept 2026neutral

The item is a transcript of a Seeking Alpha call discussing Corbus Pharmaceuticals Holdings, Inc.'s Phase 1b topline results for CRB-913 in obesity and its potential as a weight loss therapy. It covers the presentation of these trial results and the compound's outlook.

Why it matters — CRBP watchers would care because the transcript details clinical data and developments for CRB-913, a key pipeline candidate in the obesity space.

Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects'

Benzinga · 14 Sept 2026positive

Corbus Pharmaceuticals Holdings, Inc. reported topline results from the CANYON-1 Phase 1b trial of CRB-913, its obesity treatment candidate, on Monday. The drug reportedly avoided depressive effects in the trial.

Why it matters — CRBP watchers would care because the trial results address a key safety concern for obesity drugs, potentially supporting the candidate's continued development.

FAQ

Frequently asked questions about CRBP stock

What is the CRBP stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Corbus Pharmaceuticals Holdings, Inc. have a median 12-month price target of $34, with estimates ranging from $17 to $48. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRBP stock a buy right now?

Of the 9 analysts covering Corbus Pharmaceuticals Holdings, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Corbus Pharmaceuticals Holdings, Inc. 19 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRBP?

As at 8 Oct 2026, Corbus Pharmaceuticals Holdings, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (76 of 100).

Will CRBP stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +545.2% from the last close, and Ticker Nerd's factor model ranks Corbus Pharmaceuticals Holdings, Inc. 19 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRBP stock forecast for 2030?

No analyst covering Corbus Pharmaceuticals Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRBP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $48 over the next 12 months.

How has CRBP stock performed over the past year?

Corbus Pharmaceuticals Holdings, Inc. returned -60.7% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Corbus Pharmaceuticals Holdings, Inc. do?

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for oncology and obesity.

What is the latest news on CRBP?

The most recent item we track (GlobeNewsWire, 29 Sept 2026): "Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer". Corbus Pharmaceuticals announced that the first patient has been dosed in its TEMPO-1 registrational study of CRB-701, a next-generation Nectin-4 targeted antibody drug conjugate, in second-line and beyond oropharyngeal squamous cell carcinoma. The company noted that OPSCC incidence and prevalence are rising in the U.S., largely driven by HPV infection, with an estimated 14,000 patients eligible for treatment annually.

Company

About Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for oncology and obesity. Corbus Pharmaceuticals Holdings, Inc. advances a pipeline centered on targeted treatments, including CRB-701, an antibody drug conjugate designed to target Nectin-4 on cancer cells, and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist being studied for obesity. The company’s work is concentrated on well-defined biological pathways and on creating medicines that address serious diseases through precision-focused mechanisms. Corbus Pharmaceuticals Holdings, Inc. plays a role in the biotechnology market as a developer of investigational drug candidates aimed at cancer and metabolic disease, with its current programs spanning clinical research and product development in these therapeutic areas.

CEO Dr. Yuval Cohen Ph.D. · 36 employees · United States · https://www.corbuspharma.com